Driving change.

For those you care for

Focusing on the development of new drugs for the treatment of inflammatory diseases

Our mission

Temisis is a therapeutic company focusing on the development of small-molecule assets for the treatment of unmet needs in pathologies possessing a strong inflammatory component.


Temisis is committed to developing small therapeutic molecules to fulfil unmet needs in pathologies involving IL-17/23 axis of inflammation.

Upcoming events

25mar(mar 25)8 h 00 min27(mar 27)18 h 00 minBIO Europe Spring 2019Vienna, Austria

25apr(apr 25)8 h 00 min27(apr 27)18 h 00 minSPIN 2019 - Skin Inflammation & Psoriasis International Network CongressParis, France

21mayAll Day23Dermatology Drug Development Summit Europe


Share with us on Derm Drug Development Summit 2019 during our talk about TEM1657 – A Novel Small Molecule Approach Targeting Psoriasis.


Our main asset in dermatology, TEM1657, is a brand-new small molecule that shows similar efficacy as market reference corticosteroids at pre-clinical stage to remit psoriasis symptoms but without the common side effects that are associated.


Rapid efficacy

Symptoms are significantly reduced after the first application of TEM1657.


Complete remission of psoriasis symptoms

No erythema – Regulated desquamation – Normal skin thickness.


No side effect

No skin thinning (unlike corticosteroids), no observed side effect on animals in toxicity tests.



Temisis is sharing latest non-confidential data about the development of TEM1657 with interested partners and potential investors.

Contact us

19 av de la Forêt de Haye,
54500 Vandœuvre-lès-Nancy
Tel.: +33 (0) 383 940 342